Aquinox Pharmaceuticals, Inc. (AQXP)

[kingsransome]

wha happen$ when she break$ 15 fity $$$$

[Lone Wolf]

Volume. Interesting. Back on watch.

[beambe]

GREEN

[OB_WEALTH_INC]

THANKS SM

[TheFinalCD]

GOOD CALL PD

AQXP @ $12 GAP FILLED..might be ready for a bounce! Protection sell $11.50. Risk 5% to 7% vs reward upside potential is $24 = 100% potential.

[OB_WEALTH_INC]

AQXP @ $12 GAP FILLED..might be ready for a bounce! Protection sell $11.50. Risk 5% to 7% vs reward upside potential is $24 = 100% potential.

[kingsransome]

our creme bio's are separating from the stupid ibb etf's being shorted ,watch what happens now $$$$$$$

[kingsransome]

$28+ trend peep$$$$$$$ myop upgraded sweet new$$$$

[kingsransome]

All in again gap filled myop

[oxnous]

At least I ducked this one. No payoff for heroes here.

[ash111]

.

[kingsransome]

wall_city12 • 24 minutes ago

1
users liked this posts
users disliked this posts
0
Reply

Leerink: Time To Buy Aquinox Pharma - details

Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) shares have jumped 145 percent year-to-date.

Leerink’s Paul Matteis initiated coverage of the company with an Outperform rating and a price target of $26.

Encouraging Phase II results of the company’s lead product and BPS unmet need support a favorable risk/reward, Matteis said.

The clinical utility of Aquinox Pharmaceuticals’ lead product AQX-1125, a SHIP1 activator, is being studied in Bladder Pain Syndrome [BPS] or Interstitial Cystitis [IC] as well as several other inflammatory diseases. The company has already registered encouraging Phase II data for AQX-1125, and is now advancing into a Phase III study, analyst Paul Matteis said.

“Recent Phase II '1125 BPS/IC study showed a very strong primary endpoint trend and a stat. sig. benefit on a battery of secondary endpoints, one of which (max daily pain) we believe is likely to serve as the primary efficacy measure in Phase III,” Matteis wrote.

In the report Leerink noted, “While not specific to BPS/IC, recent FDA analgesic indication guidelines support use of maximum daily pain as a registrational endpoint, on which AQX-1125 generated a more robust benefit (p=.03) in Phase II.”

Matteis believes that AQX-1125 may easily exceed the sales of Elmiron, the only currently approved oral product for BPS/IC, if its late stage studies succeed and the company gets FDA approval.

The company plans to hold an R&D day on October 7, besides holding an end-of-Phase II meeting with the FDA in 4Q15. Matteis added that Aquinox Pharmaceuticals is conducting a Phase II study of '1125 in Atopic Dermatiti

[kingsransome]

news out,,outperform rating $28 price target

[kingsransome]

Why is ihub posting old news on many stocks? Hmmmm

[Atlanta1]

what does that have to do with AQXP?

[Atlanta1]

in at $18.28 after the dip.

$AQXP

[kingsransome]

NEWS OUT,,SHORTS TOAST $$$$

[kingsransome]

here we go $19+ pivyyyyyyyyyyy $$$$$$$$$$ myop

[beambe]

GO $ 13

[TheFinalCD]

TURD JUST HIT $17'S

WOW WHAT MANIPULATION

[kingsransome]

all in on gap from 25,,we spike $30 nxt up myop

[crudeoil24]

Need Baker Brothers to buy more shares...LOL

[TheFinalCD]

AQXP TRYING TO BREAK OVER $19 AGAIN

TRYING= KEY WORD

[beambe]

No

[TheFinalCD]

BB G&T SO FAR THIS MORN $25'S-$18'S

[3kidsplus1]

Watch!

[beambe]

No-no

[crudeoil24]

Check this out: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116949185

[crudeoil24]

I know, that's cool!

[Arizzle]

BB bought all of those, look at the filings. That's why it jumped AH on Friday.

[3kidsplus1]

$30-50+ coming! $AQXP

[crudeoil24]

You bet! > From SEC Form 424(b)(5): "We are offering $75,000,000 of shares of our common stock."

Sept. 8, 2015

[zazookaz]

i think dilution coming.

[beambe]

VOLUME

[tripil7z]

$AQXP $24

[kei]

AQXP - thank you ash!! - comment from yahoo poster:
why would you talk to the fda unless you knew something that would require fda review/approval?

my bet guess is the results now show permanent pain reduction at 12 week or so as opposed to the original pain reduction at 6 weeks as reported; the pain free effect is long lasting

"We believe the next steps for AQX-1125 in BPS/IC include finalizing our pivotal trial designs in consultation with the appropriate regulatory authorities, including the FDA and EMA, to set a path to potential approval," added Mr. Main.

More relevant to you on the call today is our intent to hold a research day in New York in early October with our team and an independent key opinion leader in attendance. The purpose of this event will be to review the current state of BPS/IC, our LEADERSHIP full results, as well as discuss our proposed pivotal trial program.

The specific date and location has not yet been set, but we will communicate this as soon as that information is available. And of course, we hope that those of you in New York City can participate in person, while a webcast will be available for everyone else

[ash111]

great DD.

[kei]

AQXP: near-term catalysts:

1) financing will be closed this tuesday
2) data presentation this friday in rome (early morning here in the u.s.)
3) october - another data presentation - ceo mentioned an analyst day in early oct in nyc in last report
4) november - will meet with FDA (canacord mentioned it in their report on friday; first time we had heard of that; i think that is pretty important news on the original pr on the results, aqxp said they would disucss with regulatory bodies the path forward and looks like the meeting is set)

[OB_WEALTH_INC]

EASY $$$ AQXP

[Mark]

I know, Baker Bros at it again buying up the offering, thought about taking some A/H but didn't. Might gap to 25+ on Monday and go big again.

[TheFinalCD]

DOES THAT MEAN YOU SOLD?



Message in reply to:

Its solid but more chances for this to go down rather than higher.imo




AS OF TODAYS CLOSE AQXP IS UP +1150.72% FROM ITS 52W LOW SO FAR



2015/08/07 2.43 11.68 2.43 10.5400 61,997,139 10.5400
2015/08/06 1.71 1.79 1.65 1.71 79,737 1.71

[TheFinalCD]

Short Float 12.67%


THATS WHAT FINVIZ SHOWS= http://www.finviz.com/quote.ashx?t=AQXP

[tripil7z]

$AQXP 38% of float is SHORT...OUCH !!! Shorts will be in trouble on Monday... pic.twitter.com/LhJVPi7jQV

— Antonio Costa (@ACInvestorBlog) September 11, 2015

[bfavre40]

Where did you find the 38% short float number? Not sure where some are getting that as short interest reported by monthly and last report was about 11%?

[TheFinalCD]

AQXP: Sep 2015 Canaccord Genuity Maintains Buy

http://www.benzinga.com/calendar/ratings?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site

[TheFinalCD]

Aquinox Has 33% Upside As These Four Catalysts Come Near

.

Benzinga
By Patrick Williams
10 hours ago

.
• Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) shares have lost 13 percent over the past month, trading far below their 52-week high of $55.75.
• Canaccord Genuity’s Corey Davis maintained a Buy rating for the company, while raising the price target from $10 to $22.
• The company is expected to launch a BPS/IC indication on its own, Davis said, estimating U.S. sales to grow from $13 million in 2019 to $273 million in 2025.

Earlier in June, AQX-1125's Phase II LEADERSHIP trial in BPS/IC missed its primary endpoint of reduction in average daily pain after six weeks. On August 6, the company revealed “a preponderance of positive results from multiple pre-specified secondary endpoints that revived the stock -- and our view on the chance for success,” analyst Corey Davis said.

In the report Canaccord Genuity noted the most clinically meaningful data points as:
1. Numerical separation from placebo for all pain endpoints as early as two weeks
2. Loss of efficacy was seen almost immediately in the two-week follow-up after six weeks of treatment
3. Statistically significant reduction in "maximum daily pain scores," with the primary being "average daily pain"
4. Significantly reduced O'Leary-Sant ICSI/PI, a validated, patient reported outcome measure.

“So even though the trial technically failed, there's plenty of supporting evidence to conclude that AQX-1125 has therapeutic potential in IBS/IC. We'll know more after the meeting with FDA in Nov. As a result, we are now only including IBS/ IC in our model and assuming no partnership,” Davis wrote.

U.S. sales are expected to grow from $13 million in 2019 to $273M in 2025, which could prove conservative. “And with nothing else in development we are aware of, Aquinox could own the lion's share of the market given its already very clean safety profile and 1x daily oral dosing,” the report added.

[TheFinalCD]

HOW ABOUT $22


AMAZING SHHHHIT!

[TheFinalCD]

OF COURSE I GO OUT TO EAT AFTER GETTING BEAT UP ON AVP, & VVUS

AND THIS ONE ROCKETS

[logic_guy]

In fact Aug They made many [purchases at 7 to 10 and reduced float to 250K to make it go $50 almost
http://www.streetinsider.com/13Ds/Aquinox+Pharma+(AQXP)+Adds+to+Gains+as+Baker+Brothers+Takes+Stake+to+40%25/10796779.html

[tripil7z]

$AQXP $22.05 in AH if this breaks $24.50 with a 38% short float then $50 will be in play.